Ten-year experience in transplantation of A sub(2) kidneys into B and O recipients

This article summarizes our 10-year multicenter experience with transplantation of 50 blood group A sub(2) and A sub(2)B kidneys into B and O patients. Since 1986, we have transplanted kidneys from 46 cadaver donors and 4 living donors who were blood group A sub(2) (47 donors) or A sub(2)B (3 donors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation 1998-01, Vol.65 (2), p.256-260
Hauptverfasser: Nelson, P W, Landreneau, MD, Luger, A M, Pierce, GE, Ross, G, Shield, CF III, Warady, BA, Aeder, MI, Helling, T S, Hughes, T M, Beck, M L, Harrell, K M, Bryan, C F
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This article summarizes our 10-year multicenter experience with transplantation of 50 blood group A sub(2) and A sub(2)B kidneys into B and O patients. Since 1986, we have transplanted kidneys from 46 cadaver donors and 4 living donors who were blood group A sub(2) (47 donors) or A sub(2)B (3 donors) into 19 B and 31 O patients. In 1991, we began allocating these kidneys preferentially to B and O recipients who were selected based on a history of low ( less than or equal to 4) anti-A IgG isoagglutinin titers. Immunosuppression was no different from that used in ABO-compatible grafts. The 1-month function rate before thus selecting the patients was 68% (19/28), but is now 94% (17/18). Two-year cadaver-donor graft survival with this selection method is 94%, compared with 88% for 640 concurrent and consecutive ABO-compatible transplants (log-rank, 0.15). All four living-related transplants are still functioning, with a mean follow-up of 71 months. Since we began allocating A sub(2) kidneys preferentially to B and O recipients, the percentage of the B patients who received A sub(2) or A sub(2)B kidneys has increased from 29% (8/28) to 55% (10/18). Transplantation of A sub(2) or A sub(2)B kidneys into B and O patients is clinically equivalent to that of ABO-compatible transplantation when recipients are selected by low pretransplant anti-A titer histories. This approach increases access of blood group B recipients to kidneys.
ISSN:0041-1337